Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
← catalyst calendarNCT06223516 · readout ≤ 192 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
60actual
Sites
15
Countries
Germany, Israel, Japan +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-17 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Interventions
- Drug: Subcutaneous (SC) Etentamig
- Drug: Intravenous (IV) Etentamig
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Experiencing Cytokine Release Syndrome (CRS) Events
measured Up to 2 cycles (56 days)
Percentage of Participants Experiencing Immune Cell-Associated Neurotoxicity Syndrome (ICANS) Events
measured Up to 2 cycles (56 days)
Maximum Observed Concentration (Cmax) of ABBV-383
measured Up to 32 weeks
Time to Cmax (Tmax) of ABBV-383
measured Up to 32 weeks
Trough Concentration (Ctrough) of ABBV-383
measured Up to 32 weeks
Area Under the Plasma Concentration-time Curve (AUC) of ABBV-383
measured Up to 24 weeks
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed